Loading...
Header Logo
Keywords
Last Name
Institution

Dr Marijke Becx-Bleumink

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Angra P, Becx-Bleumink M, Gilpin C, Joloba M, Jost K, Kam KM, Kim SJ, Lumb R, Mitarai S, Ramsay A, Ridderhof J, Rieder HL, Selvakumar N, van Beers S, van Cleeff M, Van Deun A, Vincent V. Ziehl-Neelsen staining: strong red on weak blue, or weak red under strong blue? Int J Tuberc Lung Dis. 2007 Nov; 11(11):1160-1. PMID: 17958975.
      View in: PubMed
    2. Begum V, van der Werf MJ, Becx-Bleumink M, Borgdorff MW. Viewpoint: do we have enough data to estimate the current burden of tuberculosis? The example of Bangladesh. Trop Med Int Health. 2007 Mar; 12(3):317-22. PMID: 17313503.
      View in: PubMed
    3. Becx-Bleumink M, Gondrie PC, van Gorkom J. [The Dutch contribution to worldwide tuberculosis control: Royal Netherlands Association for the Prevention of Tuberculosis (KNCV) Tuberculosis Foundation]. Ned Tijdschr Geneeskd. 2003 Sep 20; 147(38):1875-8. PMID: 14533503.
      View in: PubMed
    4. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb). 2003; 83(1-3):183-6. PMID: 12758210.
      View in: PubMed
    5. Becx-Bleumink M, Wibowo H, Apriani W, Vrakking H. High tuberculosis notification and treatment success rates through community participation in central Sulawesi, Republic of Indonesia. Int J Tuberc Lung Dis. 2001 Oct; 5(10):920-5. PMID: 11605885.
      View in: PubMed
    6. van Gorkom J, van Cleeff M, Becx-Bleumink M, Veen J. Short-course instead of long-course chemotherapy for smear-negative patients in sub-Saharan Africa. Int J Tuberc Lung Dis. 2001 Jan; 5(1):4-11. PMID: 11263514.
      View in: PubMed
    7. Nagelkerke NJ, Borgdorff MW, Kalisvaart NA, Broekmans JF. The design of multi-stage tuberculin surveys: some suggestions for sampling. Int J Tuberc Lung Dis. 2000 Apr; 4(4):314-20. PMID: 10777079.
      View in: PubMed
    8. Becx-Bleumink M, Djamaluddin S, Loprang F, de Soldenhoff R, Wibowo H, Aryono M. High cure rates in smear-positive tuberculosis patients using ambulatory treatment with once-weekly supervision during the intensive phase in Sulawesi, Republic of Indonesia. Int J Tuberc Lung Dis. 1999 Dec; 3(12):1066-72. PMID: 10599009.
      View in: PubMed
    9. Borgdorff MW, Nagelkerke NJ, van Soolingen D, Broekmans JF. Transmission of tuberculosis between people of different ages in The Netherlands: an analysis using DNA fingerprinting. Int J Tuberc Lung Dis. 1999 Mar; 3(3):202-6. PMID: 10094320.
      View in: PubMed
    10. Becx-Bleumink M, Broekmans JF. Tuberculosis: where do we stand? Trop Med Int Health. 1998 Jun; 3(6):423-4. PMID: 9657503.
      View in: PubMed
    11. Bosman MC, Swai OB, Kwamanga DO, Agwanda R, Idukitta G, Misljenovic O. National tuberculin survey of Kenya, 1986-1990. Int J Tuberc Lung Dis. 1998 Apr; 2(4):272-80. PMID: 9559397.
      View in: PubMed
    12. Ipuge YA, Rieder HL, Becx-Bleumink M, Kimerling ME. Evaluation and planning in national tuberculosis control programmes: the usefulness of the standardised patient treatment card. East Afr Med J. 1997 Dec; 74(12):816-8. PMID: 9557430.
      View in: PubMed
    13. Noordeen SK, Roxas MG, Fine PE, Smith WC, Feenstra P, Gokhale SD, Joo LK, Huan-Ying L, Khalafalla G, Becx-Bleumink M, Srinivasan H, Rao CK, Lechat MF, Sansarricq H. Eliminating leprosy as a public health problem--is the optimism justified? World Health Forum. 1996; 17(2):109-44. PMID: 8936264.
      View in: PubMed
    14. Becx-Bleumink M. Cotrifazide. Indian J Lepr. 1994 Jan-Mar; 66(1):69-71. PMID: 7983395.
      View in: PubMed
    15. Becx-Bleumink M. Multidrug therapy in the control of leprosy. A field study. Trop Geogr Med. 1994; 46(2):109-14. PMID: 8079385.
      View in: PubMed
    16. Becx-Bleumink M. Success of the WHO multidrug therapy? Trop Geogr Med. 1994; 46(2):61-4. PMID: 8079392.
      View in: PubMed
    17. Becx-Bleumink M. Comment: 'The allocation of leprosy patients into paucibacillary and multibacillary groups for multidrug therapy, taking into account the number of body areas affected by skin, or skin and nerve lesions'. Lepr Rev. 1993 Sep; 64(3):281. PMID: 8231611.
      View in: PubMed
    18. Becx-Bleumink M. Priorities for the future and prospects for leprosy control. Int J Lepr Other Mycobact Dis. 1993 Mar; 61(1):82-101. PMID: 8326185.
      View in: PubMed
    19. Becx-Bleumink M. Duration of multidrug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992 Sep; 60(3):436-44. PMID: 1474282.
      View in: PubMed
    20. Becx-Bleumink M. Relapses among leprosy patients treated with multidrug therapy: experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Int J Lepr Other Mycobact Dis. 1992 Sep; 60(3):421-35. PMID: 1474281.
      View in: PubMed
    21. Becx-Bleumink M, Berhe D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992 Jun; 60(2):173-84. PMID: 1522359.
      View in: PubMed
    22. Becx-Bleumink M. Relapses in leprosy patients after release from dapsone monotherapy; experience in the leprosy control program of the all Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis. 1992 Jun; 60(2):161-72. PMID: 1522358.
      View in: PubMed
    23. Becx-Bleumink M. Experience with WHO-recommended multidrug therapy (MDT) for multibacillary (MB) leprosy patients in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center in Ethiopia: appraisal of the recommended duration of MDT for MB patients. Int J Lepr Other Mycobact Dis. 1991 Dec; 59(4):558-68. PMID: 1802938.
      View in: PubMed
    24. Becx-Bleumink M. Allocation of patients to paucibacillary or multibacillary drug regimens for the treatment of leprosy--a comparison of methods based mainly on skin smears as opposed to clinical methods--alternative clinical methods for classification of patients. Int J Lepr Other Mycobact Dis. 1991 Jun; 59(2):292-303. PMID: 2071986.
      View in: PubMed
    25. Mahon AC, Nurlign A, Kebede B, Becx-Bleumink M, Lefford MJ. Urinary phenolic glycolipid 1 in the diagnosis and management of leprosy. J Infect Dis. 1991 Mar; 163(3):653-6. PMID: 1995739.
      View in: PubMed
    26. Hancock GE, Molloy A, Ab BK, Kiessling R, Becx-Bleumink M, Cohn ZA, Kaplan G. In vivo administration of low-dose human interleukin-2 induces lymphokine-activated killer cells for enhanced cytolysis in vitro. Cell Immunol. 1991 Feb; 132(2):277-84. PMID: 1988157.
      View in: PubMed
    27. Converse P, Ottenhoff TH, Work Teklemariam S, Hancock GE, Dietz M, Becx-Bleumink M, Wondimu A, Kiessling R, Cohn ZA, Kaplan G. Intradermal recombinant interleukin 2 enhances peripheral blood T-cell responses to mitogen and antigens in patients with lepromatous leprosy. Scand J Immunol. 1990 Aug; 32(2):83-91. PMID: 2389115.
      View in: PubMed
    28. Becx-Bleumink M, Berhe D, Mannetje W. The management of nerve damage in the leprosy control services. Lepr Rev. 1990 Mar; 61(1):1-11. PMID: 2319899.
      View in: PubMed
    29. Kaplan G, Kiessling R, Teklemariam S, Hancock G, Sheftel G, Job CK, Converse P, Ottenhoff TH, Becx-Bleumink M, Dietz M, et al. The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2. J Exp Med. 1989 Mar 01; 169(3):893-907. PMID: 2494293; PMCID: PMC2189266.
    30. Becx-Bleumink M. Multiple drug therapy: implications for field work and training at ALERT. Ethiop Med J. 1986 Dec; 24 Suppl 1:69-80. PMID: 3609001.
      View in: PubMed
    31. Becx-Bleumink M. Multiple drug therapy: implications for field work and training at ALERT (All Africa Leprosy and Rehabilitation Training Centre). Lepr Rev. 1986 Dec; 57 Suppl 1:69-80. PMID: 3586836.
      View in: PubMed
    32. Becx-Bleumink M. Implementation of multidrug therapy in the ALERT Leprosy Programme in the Shoa Region of Ethiopia. First results with paucibacillary patients. Lepr Rev. 1986 Jun; 57(2):111-9. PMID: 3747703.
      View in: PubMed
    33. van Asbeck-Raat AM, Becx-Bleumink M. Monitoring dapsone self-administration in a multidrug therapy programme. Lepr Rev. 1986 Jun; 57(2):121-7. PMID: 3747704.
      View in: PubMed
    34. Becx-Bleumink M. Operational aspects of the implementation of multidrug therapy at ALERT, Ethiopia. Lepr Rev. 1986; 57 Suppl 3:115-23. PMID: 3573951.
      View in: PubMed
    Becx-Bleumink's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description